PharmaBoardroom

As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland.…

Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause…

Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant…

The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to…

Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company…

LEO Pharma’s Country Lead for Switzerland, Patrick Brunner, discusses the skincare specialist’s most important products, the Swiss affiliate’s…

The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster,…

Ensuring a fair allocation of rights and returns from collaboratively developed technologies is a continual challenge for university Tech Transfer…

Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international…

Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in…

Ulf Claesson provides a fascinating and passionate account of how his firm is aiming to remove ‘guesswork’ and estimations for medical practices…

Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure…